Search clinical trials for: HR breast cancer

Total 99490 results

Roswell Park Cancer Institute

Not yet recruiting

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Unresectable Triple-Negative Breast Carcinoma

United States
Beijing Geekgene Technology Co., LTD

Recruiting

a Single-arm, Single-center, Open Clinical Study (GK-01)

Cervical Cancer | Gastric Cancer | Esophageal Cancer | Non-Small Cell Lung Cancer NSCLC | Triple Negative Breast Cancer TNBC

China
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Not yet recruiting

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics (COSMIC)

Melanoma | Non-Hodgkin Lymphoma | Breast Carcinoma | Lung Non-Small Cell Carcinoma | Colorectal Carcinoma
Fudan University

Not yet recruiting

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer (QUEEN-Neo)

Neoadjuvant Therapy | Early Breast Cancer | HR+HER2- Breast Cancer
Eli Lilly and Company
Loxo Oncology, Inc.

Recruiting

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Uterine Cervical Neoplasms | Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Triple Negative Breast Neoplasms | Pancreatic Neoplasm

United States
Henan Cancer Hospital

Not yet recruiting

Serplulimab Plus Chemotherapy for Early-stage ER+/HER2- Breast Cancer

Breast Cancer

China
Gene Solutions
University of Medicine and Pharmacy at Ho Chi Minh City

Recruiting

Clinical Validation of an MCED Test in Symptomatic Populations (K-ACCELERATE) (K-ACCELERATE)

Cancer, Breast | Cancer, Lung | Cancer Colon | Cancer, Gastric | Cancer, Liver

Vietnam
RemeGen Co., Ltd.

Recruiting

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

Breast Cancer

China
Mayo Clinic

Recruiting

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients

Metastatic Breast Cancer | HER2-negative Breast Cancer | Hormone-receptor-positive Breast Cancer

United States
Shanghai Escugen Biotechnology Co., Ltd

Not yet recruiting

A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Metastatic Breast Cancer

China
Milton S. Hershey Medical Center

Not yet recruiting

Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2

Melanoma | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Liver Cancer | Genito-Urinary Cancer

United States
Cancer Research UK
UCB Biopharma SRL

Not yet recruiting

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

Uterine Cervical Neoplasms | Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Pancreatic Neoplasms | Esophageal Neoplasms | Ovarian Neoplasms | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Advanced Solid Tumours | Carcinoma, Renal Cell (Clear Cell Only) | Stomach Neoplasms...

United Kingdom
AstraZeneca

Not yet recruiting

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (EvoPAR-BR01)

Advanced Breast Cancer

Canada
Institut de cancérologie Strasbourg Europe
Continuum Plus Santé; Plateforme nationale qualité de vie et cancer; WeShare

Recruiting

Impact on Quality of Life and Health of the CONTINUUM+ CONNECT Remote Monitoring Solution (FEGALA)

Breast Neoplasms | Lung Neoplasms | Prostatic Neoplasms | Colorectal Neoplasms

France
The First Affiliated Hospital with Nanjing Medical...
Zhejiang Cancer Hospital

Recruiting

Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

Advanced Breast Cancer

China
Washington University School of Medicine
United States Department of Defense; Aclaris Therapeutics, Inc.

Not yet recruiting

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer

United States
Puma Biotechnology, Inc.

Not yet recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer (ALISCA-Breast1)

Metastatic Breast Cancer | Recurrent Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer

United States
Beijing Friendship Hospital

Recruiting

Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis

Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Cholangiocarcinoma | Thyroid Cancer | Liver Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer

HR+HER2- Breast Cancer

China
Fudan University

Recruiting

Abemaciclib, Palbociclib or Dalpiciclib Combined With Endocrine Therapy as First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

Breast Cancer

China
Fudan University

Recruiting

Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

Breast Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer

Early Breast Cancer

China
GC Cell Corporation

Not yet recruiting

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

Breast Cancer | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Australia
The Affiliated Hospital of Qingdao University

Not yet recruiting

A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer

Neoplasms | Breast Cancer | Breast Diseases

China
Li Huiping

Not yet recruiting

A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer

Advanced Breast Cancer
Actym Therapeutics, Inc.

Not yet recruiting

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

Solid Tumor

Australia
Thomas Jefferson University

Recruiting

An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Breast Carcinoma

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Breast Neoplasms

Israel, United States, Taiwan, Hong Kong, Korea, Republic of, Switzerland
RenJi Hospital

Not yet recruiting

Dalpiciclib in HR+/HER2- ABC

Advanced Breast Cancer

China
Sun Yat-sen University

Not yet recruiting

Myeloprotection With Trilaciclib in Pan-cancer Population

Cervical Cancer | Breast Cancer | Non-Small Cell Lung Cancer | Endometrial Cancer | Head And Neck Squamous Cell Carcinomas

China
Regor Pharmaceuticals Inc.

Recruiting

A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors

Breast Cancer | Advanced Solid Tumor

China
Numab Therapeutics AG

Recruiting

NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

Renal Cell Carcinoma | Mesothelioma, Malignant | Adenocarcinoma of Lung | Triple Negative Breast Cancer | Endometrial Cancer | Fallopian Tube Carcinoma | Peritoneal Carcinoma | Leiomyosarcoma | Liposarcoma | Ovarian Carcinoma | Adenocarcinoma of the Stomach | Melanoma, Malignant | Adenocarcinoma - Gastroesophageal...

United States
Dr Jean Yannis PERENTES

Recruiting

Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration (PITHAC)

Carcinoma, Non-Small-Cell Lung | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Mesothelioma, Malignant | Carcinoma Breast Stage IV

Switzerland
Henan Cancer Hospital

Not yet recruiting

Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

Breast Cancer | HER2-positive Breast Cancer

China
BostonGene
Exigent

Not yet recruiting

BostonGene and Exigent Genomic INsight Study (BEGIN)

Melanoma | Sarcoma | Breast Cancer | Non-small Cell Lung Cancer

United States
Pliant Therapeutics, Inc.

Recruiting

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Metastatic Solid Tumor

United States
GeneMedicine Co., Ltd.

Recruiting

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Malignant Melanoma

Korea, Republic of
NiKang Therapeutics, Inc.

Recruiting

A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

Small Cell Lung Carcinoma | Gastric Cancer | Ovarian Neoplasms | Ovarian Cancer | Solid Tumor | Endometrial Neoplasms | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Advanced Solid Tumor | Endometrial Cancer | Small-cell Lung Cancer | Platinum-resistant Ovarian Cancer | Ovarian Carcinoma | Solid... and other conditions

United States
BeiGene

Recruiting

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Breast Cancer | Small Cell Lung Cancer | Gastric Cancer | Ovarian Cancer | Prostate Cancer | Advanced Solid Tumor | Endometrial Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer | Hormone-receptor-positive Breast Cancer

United States, Australia
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Breast Cancer

China
UTC Therapeutics Inc.
Peking University Cancer Hospital & Institute

Recruiting

Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors

Colorectal Cancer | Pancreatic Cancer | Rectal Cancer | Malignant Mesothelioma | Bile Duct Cancer | Breast Cancer Female | Ovary Cancer

China
BeiGene

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Breast Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Hormone Receptor Positive Malignant Neoplasm of Breast | HER2-negative Breast Cancer | Hormone-receptor-positive Breast Cancer

China
Zhejiang Cancer Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

Female Breast Cancer Patients | Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer | HRD Positive Advanced Breast Cancer
ModeX Therapeutics, An OPKO Health Company

Not yet recruiting

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Cervical Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Prostate Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Colon Cancer | Thyroid Cancer | Renal Cancer | Biliary Tract Cancer | Hepatocellular Cancer | GastroEsophageal Cancer
Eli Lilly and Company
Loxo Oncology, Inc.

Recruiting

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Cervical Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Renal Pelvis Cancer | Urinary Bladder Neoplasm | Recurrent...

United States
SOLTI Breast Cancer Research Group

Not yet recruiting

HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan (ACROSS-TROP2)

Breast Cancer Stage IV

Spain
RemeGen Co., Ltd.

Recruiting

Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

Breast Cancer

China
Shandong Suncadia Medicine Co., Ltd.

Not yet recruiting

Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer

Breast Cancer
Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

Breast Cancer

Germany
German Breast Group
GlaxoSmithKline; Stemline Therapeutics, Inc.

Not yet recruiting

Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer (ELEMENT)

BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | Hormone Receptor Positive HER-2 Negative Breast Cancer | Advanced or Metastatic Breast Cancer

Germany

Search clinical trials for: HR breast cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations